Skip to Content

IRESSA 250 (Iressa 250 mg)

Generic Name: gefitinib

Pill with imprint IRESSA 250 is Brown, Round and has been identified as Iressa 250 mg. It is supplied by AstraZeneca Pharmaceuticals.

Iressa is used in the treatment of non-small cell lung cancer and belongs to the drug class EGFR inhibitors. There is positive evidence of human fetal risk during pregnancy. Iressa 250 mg is not a controlled substance under the Controlled Substances Act (CSA).

Images for IRESSA 250

Iressa

Generic Name:
gefitinib
Imprint:
IRESSA 250
Strength:
250 mg
Color:
Brown
Size:
11.00 mm
Shape:
Round
Availability:
Prescription only
Drug Class:
EGFR inhibitors
Pregnancy Category:
D - Positive evidence of risk
CSA Schedule:
Not a controlled drug
Labeler / Supplier:
AstraZeneca Pharmaceuticals
Inactive Ingredients:
lactose monohydrate
microcrystalline cellulose
croscarmellose sodium
povidone
sodium lauryl sulfate
magnesium stearate
hypromelloses
polyethylene glycol 300
titanium dioxide
ferric oxide red
ferric oxide yellow
Note: Inactive ingredients may vary.

Get help with Imprint Code FAQs.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide